P2RY1 and chronic obstructive pulmonary disease: This could lead to the development of functionally selective P2Y1 antagonists as new generation anti‐inflammatory drugs that can be used to treat diseases like asthma, chronic obstructive pulmonary disease (COPD) or pneumonia with significant unmet clinical need.